Welcome to our dedicated page for InfuSystem Holdings SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InfuSystem Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InfuSystem Holdings's regulatory disclosures and financial reporting.
AWM Investment Company, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 1,272,296 shares of InfuSystem Holdings, Inc. common stock, representing 6.1% of the outstanding class. AWM states it is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS) and holds sole voting and sole dispositive power over the shares held by SSLS. The filing discloses Delaware organization for AWM, the issuer's principal office in Rochester Hills, Michigan, and confirms the stake was acquired and is held in the ordinary course of business, not for the purpose of changing control.